Aurinia's third-quarter revenue rose 13.9% to $83.7M, while net income was nearly flat at $31.7M as income tax expense increased to $7.0M from $411,000.

Filed October 30, 2026 · Period ending September 30, 2026 · Compared to 10-Q Nov 4, 2025 · ~2 min read

Key Changes

• high

  Total revenue increased 13.9% to $83.7M in the third quarter, with net product sales of LUPKYNIS up 12.4% to $79.4M, which the company attributes to an increase in the number of LUPKYNIS cartons sold to specialty pharmacies, driven by further lupus nephritis market penetration.

  view on EDGAR →
• high

  Income tax expense surged to $7.0M from $411,000 a year earlier, which the company attributes to The increase in the Company’s income tax expense in 2026 over the same periods in 2025 is primarily the result of the Company’s ability to utilize unrecognized deferred tax assets in 2025 to reduce the income tax expense. All unrecognized deferred tax assets were recognized in the three months ended December 31, 2025 and were not available to offset income tax expense for the three and nine months ended September 30, 2026.

  view on EDGAR →
• high

  Nine-month operating cash flow rose 46.1% to $131.5M, and the company ended the quarter with cash, cash equivalents, restricted cash and investments of $486.9 million.

  view on EDGAR →